Skip to content

About us
CYCLOPS
News
Products
Co-development
Vacancies
Contact

Menu

About us
CYCLOPS
News
Products
Co-development
Vacancies
Contact

Cyclops®

Convenient
Reliable
Easy-to-use
Easy-to-carry
Hygienic
Less Cough

About us
CYCLOPS
News
Products
Co-development
Vacancies
Contact

Menu

About us
CYCLOPS
News
Products
Co-development
Vacancies
Contact

Characterization and Formulation of Isoniazid for High-Dose Dry Powder Inhalation

I. Sibum, P. Hagedoorn, H.W. Frijlink, F. Grasmeijer

International Journal of Pharmaceutics,
2019,
11 (5)
(DOI: 10.3390/pharmaceutics11050233)

SHARE THIS POST

Recent Posts

QA officer

PureIMS gears up for abbreviated registration of Levodopa Cyclops® against OFF episodes in Parkinson’s disease with the successful completion of a comparative pharmacokinetic study

PureIMS winning the LIFE Science Innovation Award!

PureIMS initiates dose-finding study with Levodopa Cyclops™ dry powder inhaler

PureIMS secures new investment round to develop lead inhalation product and facilitate partnering activities

PureIMS names Frank Lambert to advance commercialization of its Cyclops™ Dry Powder Inhaler (DPI)

Drug Delivery to the Lungs (DDL) poster on Epinephrine Cyclops™

PureIMS present at DDL2022

PureIMS appoints Jaap Wieling, PhD, as new CEO

Levodopa Cyclops™ in Dutch magazine ‘Tijdschrift voor Neurologie en Neurochirurgie (TNN)’

Categories

Categories

Press release (12)
Publication (2)
Scientific publication (5)
Status update (3)
Vacancies (1)

Contact Us

Ceintuurbaan Noord 152
9301 NZ Roden
The Netherlands
T: +31 (0)50 – 2053 325
F: +31 (0)50 – 2053 326
E: info@pureims.com

Social media

Linkedin-in Youtube

Inspiration by Patients

© 2024 pureims